EMERGING RESEARCHER APPOINTED TO JAMES PACKER CHAIR IN MOOD DISORDERS AT UNSW Joins department with over 60 years research in Psychiatry and Mental Health to investigate Bipolar Disorder
The UNSW Discipline of Psychiatry and Mental Health is widely renowned as the pre-eminent psychiatry research department in the country and one of the leading university psychiatry research groups internationally. In 2023 it celebrated 60 Years of Psychiatry & Mental Health at UNSW Sydney.
Australian Health Journal spoke with Professor Kimberlie Dean, Head of the Discipline of Psychiatry and Mental Health at UNSW Sydney, about the recent appointment of mental health disorders expert and clinician researcher Dr Aswin Ratheesh to lead the James Packer Chair in Mood Disorders at UNSW Sydney.
Professor Dean spoke about UNSW being home to an outstanding mental health research community with key partners across the Mindgardens Neuroscience Network, welcoming Dr Ratheesh
As a leading clinical researcher in mood and psychotic disorders, Dr Ratheesh is passionate about prompt and early access to interventions for people with such conditions.
The appointment comes after prominent businessman and investor James Packer, jointly with The Packer Family Foundation, made a $7 million gift to establish the role last year.
The Chair will lead a new unit at UNSW and the Mindgardens Neuroscience Network that will conduct rigorous research in mental health, with a particular focus on mood disorders such as bipolar disease. The gift also funds a team of researchers to support the Chair.
Dr Ratheesh’s research is focused on understanding pathways leading to the onset of mood disorders and finding ways to provide effective treatments for individuals who develop such conditions. He has worked as a psychiatrist for over 12 years both in youth and adult mental health settings and has led several studies that have helped identify risk markers for future bipolar disorder.
He believes some of the current knowledge gaps in mood disorders include our ability to predict who will develop such conditions, who is at risk of worsening, and who will respond to specific treatments.
Dr Ratheesh currently leads an NHMRC Partnership grant in early intervention for bipolar disorder and is a chief investigator on a Centre of Research Excellence grant in early intervention for bipolar disorder. He co-leads the International Society of Bipolar Disorders Taskforce on Early Intervention and is an Associate Editor for the leading journal, the Australian and New Zealand Journal of Psychiatry. He has received awards from the International Early Psychosis Association and the Australasian Society for Bipolar and Depressive Disorders for his research.
You Might also like
-
Expansion of specialist training in regional & rural areas
Associate Professor Sanjay Jeganathan, Chair of the Council of Presidents of Medical Colleges (CPMC) states, ”Our rural and regional communities deserve the same access to specialist care as our cities. We’re seeing real results from our colleges’ commitment to rural training.”
-
Patient-paramedic trust can help free up emergency departments
Dr. Robbie King is a Senior Advanced Care Paramedic with the Queensland Ambulance Service and a community paramedic. He is also a lecturer at the Australian Catholic University in Brisbane. After studying paramedicine and working as a student paramedic since 2009, he recognised that most patients attended by ambulance services did not require emergency interventions.
-
Bionic eye trial shows improvements in functional vision for retinitis pigmentosa
Results of the first clinical trial of Australia’s ‘second generation’ bionic eye have demonstrated ‘substantial improvement’ in four participants’ functional vision, daily activities and quality of life over a period of more than two and a half years.
Led by the Centre for Eye Research Australia, Bionics Institute, University of Melbourne and Royal Victorian Eye and Ear Hospital, the trial findings add to interim results which showed that the second-generation bionic eye developed by Australian company Bionic Vision Technologies provided rapid improvements for four patients with blindness caused the genetic eye condition retinitis pigmentosa.